-
ALSO READ
Alembic Pharmaceuticals Q2 net profit rises 62% to Rs 2.07 billion
Alembic Pharma Q2 profit up 64% to Rs 2 bn; revenue at Rs 11.3 bn
Alembic Pharma gets US FDA nod for Xylocaine pain relief ointment
Alembic Pharma gets US health regulator approval for diabetes drug
Alembic Pharma receives US FDA approval for hypertension medicine
-
Drug firm Alembic Pharmaceuticals Thursday said it plans to raise up to Rs 5 billion through the issue of non-convertible debentures (NCDs) on private placement basis.
The company's board of directors Thursday approved the issue of unsecured listed redeemable NCDs of up to Rs 5 billion on private placement basis under a shelf disclosure document in multiple tranches, Alembic Pharmaceuticals said in a filing to the BSE.
The board also constituted NCD Committee for issue and allotment of NCDs, it added.
The company, however, did not disclose what it intends to do with the raised money.
Shares of Alembic Pharmaceuticals were Thursday trading at Rs 615.90 per scrip on the BSE, down 2.05 per cent from their previous close.
RECOMMENDED FOR YOU